JCRR.F Stock Overview
Engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
JCR Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4.57 |
| 52 Week High | JP¥6.20 |
| 52 Week Low | JP¥4.30 |
| Beta | 0.027 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| JCRR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 2.0% |
| 1Y | n/a | 13.7% | 32.4% |
Return vs Industry: Insufficient data to determine how JCRR.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how JCRR.F performed against the US Market.
Price Volatility
| JCRR.F volatility | |
|---|---|
| JCRR.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: JCRR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine JCRR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | 934 | Shin Ashida | www.jcrpharm.co.jp |
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease.
JCR Pharmaceuticals Co., Ltd. Fundamentals Summary
| JCRR.F fundamental statistics | |
|---|---|
| Market cap | US$602.57m |
| Earnings (TTM) | -US$2.87m |
| Revenue (TTM) | US$231.28m |
2.5x
P/S Ratio-205.2x
P/E RatioIs JCRR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JCRR.F income statement (TTM) | |
|---|---|
| Revenue | JP¥35.26b |
| Cost of Revenue | JP¥10.07b |
| Gross Profit | JP¥25.19b |
| Other Expenses | JP¥25.62b |
| Earnings | -JP¥437.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.59 |
| Gross Margin | 71.44% |
| Net Profit Margin | -1.24% |
| Debt/Equity Ratio | 49.8% |
How did JCRR.F perform over the long term?
See historical performance and comparison